#SFHS2608598AOrder of April 9, 2026 Modifying the List of Reimbursable Pharmaceutical Specialties for Social Insured Persons
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This regulation updates the list of medications reimbursable by French social insurance, specifically adding treatments for chronic hypoparathyroidism in adults who are not adequately controlled by vitamin-calcium therapy. It specifies that treatments must be managed by qualified healthcare professionals. This impacts pharmaceutical companies and healthcare providers in France.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds reimbursable medications for chronic hypoparathyroidism in adults
- Requires management of treatments by qualified healthcare professionals
- Updates France's social insurance reimbursement list
Obligations
What this law requires
Add YORVIPATH (palopegteriparatide) in three formulations (168 mg/0.56 ml, 294 mg/0.98 ml, and 420 mg/1.4 ml injectable solutions) to the list of reimbursable pharmaceutical specialties for social insured persons
Restrict reimbursement of YORVIPATH to treatment of chronic hypoparathyroidism in adults who are not adequately controlled by vitamin-calcium therapy and require PTH substitution therapy
Ensure treatment with YORVIPATH is initiated and supervised only by qualified and experienced healthcare professionals with expertise in diagnosis and management of hypoparathyroidism
Implement the reimbursement changes effective on the fifteenth day following publication in the Journal officiel de la République française
Ensure prescribing physicians and healthcare providers verify patient eligibility criteria (chronic hypoparathyroidism inadequately controlled by vitamin-calcium therapy) before initiating YORVIPATH treatment